Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.

Also called NCT01150357

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 267 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01150357
  • EudraCT 2009-017028-22
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Germany, Guatemala, Hungary, Poland, Puerto Rico, Slovakia, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01150357. Randomized; double masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Condition
Hypertension
Intervention (Drug)
Aliskiren (6.25/12.5/25 mg)
Intervention (Drug)
Aliskiren (37.5/75/150 mg)
Intervention (Drug)
Aliskiren (150/300/600 mg)
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01150357
Content hash
2384f0ae8e81584740fd9f2554253e522127841772b3b4e19f6525b695a06e86